CLEAR-LC

Study to Investigate the Efficacy of Abrocitinib in Adult Participants with Severe Fatigue from Post COVID Condition/Long COVID

The purpose of this research study is to evaluate the effect of abrocitinib for the treatment of non-hospitalized adult participants with moderate to severe symptoms of PCC, also called “Long COVID”.

For more information, please refer to this website

You may qualify for this study if you meet the following criteria:-

18-65 years old
History of confirmed COVID-19 infection more than 30 days ago
Willing and able to come to BIDMC for 6 in-person visits over 5 months
Ongoing COVID symptoms for at least 2 months that cannot be explained by another diagnosis. (This study may be right for you if you are experiencing a post COVID condition of fatigue)
Otherwise generally healthy
No other acute or chronic infections
Not currently pregnant or breastfeeding

Name*
First Last
Email*
Phone*
Consent
I would like to receive information on other Center for Virology and Vaccine Research studies.
Which study are you interested in?*
How did you hear about this study?*
If you learned about our study through other means, please specify here.
Preferred method of contact*
- Phone
- Email
- Either
CAPTCHA

CLEAR-LC

Center for Virology and Vaccine Research

CVVR Clinical Trials Unit

Affiliates